• ZyCov D: India's first needle-free Covid-19 vaccine launched

    National
    ZyCov D: India's first needle-free Covid-19 vaccine launched
    Digital Desk: India developed its first needle-free Covid-19 vaccine named ZyCov D. It is India's second indigenous Covid-19 vaccine launched in Bihar's Patna.

    This Covid-19 needle-free vaccine brings relief for those individuals who fear needles. This vaccine is distributed at three vaccination bases in Patna- Patliputra Sports Complex, Polytechnic College and Gurunanak Bhawan. The vaccines will be given to the people in three doses.

    "The firm which has developed the vaccine has begun the supplies of its Covid-19 vaccine ZyCoV-D to the government of India against their order from its recently authorised, state-of-the-art Zydus Vaccine Technology Excellence Centre at the Zydus Biotech Park in Changodar, Ahmedabad," stated the firm in a statement.

    The Indian government in 2021 placed an order for 10 million vaccine shots for the national anti-Covid immunisation drive. The vaccine production firm is additionally preparing to make the vaccine unrestricted in the market.

    ZyCoV-D is the world's foremost plasmid DNA vaccine. A three-dose vaccine should be given intradermally utilising the effortless PharmaJet needle-free technique known as Tropis on day 0, day 28 and 56.

    Also Read: China Support Russia in NATO Showdown Over Ukraine

    According to the company, the needle-free ZyCoV-D vaccine will cost ₹265 per dose and the applicator ₹93 per dose excluding GST. The company further added that it had signed an accord with Shilpa Medicare Limited, an agreement manufacturing association, to deliver doses of ZyCoV-D. 

    It even has a pact with Enzychem Lifesciences of the Republic of Korea for the vaccine's manufacturing license and technology transfer.

    "Zydus VTEC manufactures the drug substance for the needle-free DNA Plasmid vaccine, ZyCoV-D. In the notification, the manufacturing process and in-process material transfers within the plant are automated," Zydus stated in the notification.

    The national drugs controller gave the vaccine license for restricted usage in emergencies for individuals aged 12 and above. The firm earlier reported that it should have approximately 10-12 million doses per month.